CASH COW

[apollo1452]

GALE holds Patent License 4combo use of NeuVax+Herceptin.

Roche's Herceptin has long been the dominant breast cancer drug on the market. but their patent expired in 2014 for Europe and the USA patent expires in a couple of years--which will open the way for biosimilars now in development--Roche has a limited window open to capitalize on the opportunity. That's one major reason there is speculation about Roche-Genentech being the lead suitor for GALE in the event of a Buyout if the NeuVax Interim Analysis confirms efficacy at the end of Q2 2016. Just as the CPXX double-stage moonshot showed us, the NeuVax IDMC Interim Analysis could be merely Stage One for GALE's potential Moonshot IMO.